DUBLIN--(BUSINESS WIRE)--The "Neuroblastoma - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Neuroblastoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 27, 20, 1, 48, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 5, 13 and 3 molecules, respectively.
Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Neuroblastoma - Overview
- Neuroblastoma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Neuroblastoma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Neuroblastoma - Companies Involved in Therapeutics Development
Companies Mentioned
- Ability Pharmaceuticals SL
- Actuate Therapeutics Inc
- Bexion Pharmaceuticals LLC
- BioLineRx Ltd
- Biotec Pharmacon ASA
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Co
- Cancer Prevention Pharmaceuticals Inc
- Cebiotex SL
- Celgene Corp
- Celldex Therapeutics Inc
- Cielo Therapeutics Inc
- Cleveland BioLabs Inc
- CorMedix Inc
- Curis Inc
- Cyclacel Pharmaceuticals Inc
- DEKK-TEC Inc
- EnGeneIC Ltd
- Epizyme Inc
- Errant Gene Therapeutics LLC
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline Plc
- Lindis Biotech GmbH
- Loxo Oncology Inc
- MabVax Therapeutics Holdings Inc
- MacroGenics Inc
- MediaPharma SRL
- Merck & Co Inc
- Morphogenesis Inc
- Novartis AG
- Pfizer Inc
- Phylogica Ltd
- Progenics Pharmaceuticals Inc
- Syros Pharmaceuticals Inc
- Tiltan Pharma Ltd
For more information about this report visit https://www.researchandmarkets.com/research/mrfg8n/neuroblastoma
